214 related articles for article (PubMed ID: 21375480)
61. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
Ogren SO; Kuteeva E; Hökfelt T; Kehr J
CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
[TBL] [Abstract][Full Text] [Related]
62. Molecular psychiatry. Adaptations of receptor-coupled signal transduction pathways underlying stress- and drug-induced neural plasticity.
Duman RS; Heninger GR; Nestler EJ
J Nerv Ment Dis; 1994 Dec; 182(12):692-700. PubMed ID: 7989913
[TBL] [Abstract][Full Text] [Related]
63. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder.
Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J
Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064
[TBL] [Abstract][Full Text] [Related]
64. Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator.
Machado-Vieira R
J Affect Disord; 2018 Jun; 233():92-99. PubMed ID: 29310970
[TBL] [Abstract][Full Text] [Related]
65. Antidepressant action: to the nucleus and beyond.
Malberg JE; Blendy JA
Trends Pharmacol Sci; 2005 Dec; 26(12):631-8. PubMed ID: 16246434
[TBL] [Abstract][Full Text] [Related]
66. Depression and antidepressants: molecular and cellular aspects.
Lanni C; Govoni S; Lucchelli A; Boselli C
Cell Mol Life Sci; 2009 Sep; 66(18):2985-3008. PubMed ID: 19521663
[TBL] [Abstract][Full Text] [Related]
67. Beyond serotonin: newer antidepressants in the future.
Rakesh G; Pae CU; Masand PS
Expert Rev Neurother; 2017 Aug; 17(8):777-790. PubMed ID: 28598698
[TBL] [Abstract][Full Text] [Related]
68. 5-HT and depression: is the glass half-full?
Sharp T; Cowen PJ
Curr Opin Pharmacol; 2011 Feb; 11(1):45-51. PubMed ID: 21377932
[TBL] [Abstract][Full Text] [Related]
69. Neurotrophic-priming of glucocorticoid receptor signaling is essential for neuronal plasticity to stress and antidepressant treatment.
Arango-Lievano M; Lambert WM; Bath KG; Garabedian MJ; Chao MV; Jeanneteau F
Proc Natl Acad Sci U S A; 2015 Dec; 112(51):15737-42. PubMed ID: 26630005
[TBL] [Abstract][Full Text] [Related]
70. [Multiaxial evaluation of the pathophysiology of mood disorder and therapeutic mechanisms of clinical drugs by neuronal plasticity and neuronal load].
Omata N; Mizuno T; Mitsuya H; Wada Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):231-6. PubMed ID: 25069263
[TBL] [Abstract][Full Text] [Related]
71. Cognitive role of neurogenesis in depression and antidepressant treatment.
Perera TD; Park S; Nemirovskaya Y
Neuroscientist; 2008 Aug; 14(4):326-38. PubMed ID: 18612087
[TBL] [Abstract][Full Text] [Related]
72. Translating depression biomarkers for improved targeted therapies.
Bredt DS; Furey ML; Chen G; Lovenberg T; Drevets WC; Manji HK
Neurosci Biobehav Rev; 2015 Dec; 59():1-15. PubMed ID: 26432926
[TBL] [Abstract][Full Text] [Related]
73. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Kavalali ET; Monteggia LM
Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
[TBL] [Abstract][Full Text] [Related]
74. Nucleocytoplasmic export of HDAC5 and SIRT2 downregulation: two epigenetic mechanisms by which antidepressants enhance synaptic plasticity markers.
Muñoz-Cobo I; Erburu MM; Zwergel C; Cirilli R; Mai A; Valente S; Puerta E; Tordera RM
Psychopharmacology (Berl); 2018 Oct; 235(10):2831-2846. PubMed ID: 30091005
[TBL] [Abstract][Full Text] [Related]
75. Novel strategies for pharmacotherapy of depression.
Maubach KA; Rupniak NM; Kramer MS; Hill RG
Curr Opin Chem Biol; 1999 Aug; 3(4):481-8. PubMed ID: 10419849
[TBL] [Abstract][Full Text] [Related]
76. MiR-134 modulates chronic stress-induced structural plasticity and depression-like behaviors via downregulation of Limk1/cofilin signaling in rats.
Fan C; Zhu X; Song Q; Wang P; Liu Z; Yu SY
Neuropharmacology; 2018 Mar; 131():364-376. PubMed ID: 29329879
[TBL] [Abstract][Full Text] [Related]
77. New approaches to antidepressant drug discovery: beyond monoamines.
Berton O; Nestler EJ
Nat Rev Neurosci; 2006 Feb; 7(2):137-51. PubMed ID: 16429123
[TBL] [Abstract][Full Text] [Related]
78. [Depression and neuroplasticity: implication of serotoninergic systems].
Daszuta A; Ban M; Soumier A; Hery M; Mocaer E
Therapie; 2005; 60(5):461-8. PubMed ID: 16433011
[TBL] [Abstract][Full Text] [Related]
79. Curcumin in antidepressant treatments: An overview of potential mechanisms, pre-clinical/clinical trials and ongoing challenges.
Zhang Y; Li L; Zhang J
Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):243-253. PubMed ID: 32544307
[TBL] [Abstract][Full Text] [Related]
80. Possible directions for the discovery of new antidepressant treatments.
Young SN
J Psychiatry Neurosci; 2011 Jan; 36(1):3-5. PubMed ID: 21167108
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
